Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Tailor-made Pharma Solutions

Make better informed business decisions with customized pharmaceutical consulting and marketing services that give you the edge over your competition.

Tailor-made solutions

Use the expertise and experience of Pharma Intelligence to produce custom solutions that are actionable, flexible, and tailored to help you successfully navigate biopharma portfolio management, commercial optimization, and R&D strategy. Benefit from:

A customized approach – we develop solutions to fit your situation
Joint problem/opportunity definition
Proprietary data and complementary market research
The experience of 500+ industry experts
Collaborative problem solving
Fact-based decisions and actionable recommendations
Ownership of final decisions and action plans

Discover new business opportunities, reduce risks, and make better, faster decisions with tailor-made pharmaceutical solutions from Pharma Intelligence.

Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 22 Jan 2020

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

View article
Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

21 Jan 2020

View white paper
Skipta

Skipta: Digital Clutter Infographic

17 Jan 2020

Explore the challenges in digital marketing that can make it difficult for you to directly connect with your specific target audience. Let Skipta’s exclusive perspectives be your guide.

View infographic
Pink Sheet

A Visual Guide To US FDA's Evolutionary Decade In Review

By Brenda Sandburg 16 Jan 2020

An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.

Topic FDA Policy and regulation

View analysis
Scrip

O’Day Lays Out Plan For Gilead’s Continued HIV Dominance

By Joseph Haas 15 Jan 2020

Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.

View analysis
Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

By Jung Won Shin 15 Jan 2020

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

View analysis
Generics Bulletin

California Plans To Create Own Generics Label

By Aidan Fry 15 Jan 2020

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

View analysis
HBW Insight

OTC Zantac And Private Label Ranitidine Numerous In FDA Recall Updates

15 Jan 2020

In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.

View article
HBW Insight

Bayer Harnessing Skin Microbiome In New Product Development

By Tom Gallen 15 Jan 2020

Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.

View article
Pink Sheet

EU 2019 Approvals: Novel Therapies Make Strong Showing

By Ian Schofield 15 Jan 2020

Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.

View article
Pink Sheet

Sharfstein: US FDA Incentives Not Broke, But Fix Them

By Derrick Gingery 15 Jan 2020

The former US FDA principal deputy commissioner argues that accelerated approval, fast track and breakthrough designation standards may need updating, along with orphan and pediatric exclusivity requirements, to enhance the programs' efficacy.

View analysis
Medtech Insight

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 1)

By Shawn M. Schmitt 15 Jan 2020

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this first installment of a 10-part series, a procedure for hosting inspections is addressed.

View analysis
Medtech Insight

Exec Chat: CES 2020: For FDA's Amy Abernethy It's About Data, But Also Community Engagement

By Marion Webb 15 Jan 2020

Amy Abernethy, FDA's principal deputy commissioner, sat down with Medtech Insight during CES 2020 to discuss the agency's progress on the Technology Modernization Action Plan, the pre-certification program for digital health products, and the FDA's plans for 2020.

Topic Digital Health FDA

View analysis
Citeline

Breast Cancer Clinical Landscape and Recent Trends Whitepaper

10 Jan 2020

Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.

Topic Cancer Clinical Trials Research

View white paper
HBW Insight

EU Wellness Market In 2019: The CBD Green Rush

By Tom Gallen 09 Jan 2020

An interactive timeline of HBW Insight's coverage of the blossoming European CBD market in 2019. The timeline covers the main events of the year beginning with the European Commission's decision to classify CBD as a novel food, and ending on the filing of the first application for a synthetic form of the cannabis-derived ingredient.

View infographic